BBOT BridgeBio Oncology Therapeutics | $5.52 -18.3% | 9/10/2026 | | Lower Price Target | $27.00 | Outperform | 00.00% | View details for Leerink Partners rating of BridgeBio Oncology Therapeutics (NASDAQ:BBOT) on 9/10/2026 |
PHVS Pharvaris | $37.51 -0.6% | 9/9/2026 | | Boost Price Target | $50.00 ➝ $65.00 | Outperform | 00.00% | View details for Leerink Partners rating of Pharvaris (NASDAQ:PHVS) on 9/9/2026 |
EVMN Evommune | $10.46 -3.5% | 9/9/2026 | | Lower Price Target | $28.00 ➝ $22.00 | Outperform | 00.00% | View details for Leerink Partners rating of Evommune (NYSE:EVMN) on 9/9/2026 |
BLCO Bausch + Lomb | $17.58 -1.2% | 9/9/2026 | | Initiated Coverage | $24.00 | Outperform | 00.00% | View details for Leerink Partners rating of Bausch + Lomb (NYSE:BLCO) on 9/9/2026 |
COLL Collegium Pharmaceutical | $22.92 -1.9% | 9/9/2026 | | Initiated Coverage | $45.00 | Outperform | 00.00% | View details for Leerink Partners rating of Collegium Pharmaceutical (NASDAQ:COLL) on 9/9/2026 |
AMRX Amneal Pharmaceuticals | $16.87 -2.2% | 9/9/2026 | | Initiated Coverage | $23.00 | Outperform | 00.00% | View details for Leerink Partners rating of Amneal Pharmaceuticals (NASDAQ:AMRX) on 9/9/2026 |
PHAT Phathom Pharmaceuticals | $8.37 -3.5% | 9/9/2026 | | Initiated Coverage | $10.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Phathom Pharmaceuticals (NASDAQ:PHAT) on 9/9/2026 |
HROW Harrow | $36.58 -2.6% | 9/9/2026 | | Initiated Coverage | $45.00 | Outperform | 00.00% | View details for Leerink Partners rating of Harrow (NASDAQ:HROW) on 9/9/2026 |
VTRS Viatris | $16.38 -0.7% | 9/9/2026 | | Initiated Coverage | $20.00 | Outperform | 00.00% | View details for Leerink Partners rating of Viatris (NASDAQ:VTRS) on 9/9/2026 |
AMRX Amneal Pharmaceuticals | $16.87 -2.2% | 9/9/2026 | | Initiated Coverage | $23.00 | Outperform | 00.00% | View details for Leerink Partners rating of Amneal Pharmaceuticals (NASDAQ:AMRX) on 9/9/2026 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
|
ANIP ANI Pharmaceuticals | $71.46 +1.1% | 9/9/2026 | | Initiated Coverage | $104.00 | Outperform | 00.00% | View details for Leerink Partners rating of ANI Pharmaceuticals (NASDAQ:ANIP) on 9/9/2026 |
BLCO Bausch + Lomb | $17.58 -1.2% | 9/9/2026 | | Initiated Coverage | $24.00 | Outperform | 00.00% | View details for Leerink Partners rating of Bausch + Lomb (NYSE:BLCO) on 9/9/2026 |
COLL Collegium Pharmaceutical | $22.92 -1.9% | 9/9/2026 | | Initiated Coverage | $45.00 | Outperform | 00.00% | View details for Leerink Partners rating of Collegium Pharmaceutical (NASDAQ:COLL) on 9/9/2026 |
HROW Harrow | $36.58 -2.6% | 9/9/2026 | | Initiated Coverage | $45.00 | Outperform | 00.00% | View details for Leerink Partners rating of Harrow (NASDAQ:HROW) on 9/9/2026 |
MRK Merck & Co., Inc. | $144.68 -1.9% | 9/9/2026 | | Boost Price Target | $127.00 ➝ $161.00 | Outperform | 00.00% | View details for Leerink Partners rating of Merck & Co., Inc. (NYSE:MRK) on 9/9/2026 |
NAUT Nautilus Biotechnology | $0.99 -11.6% | 9/9/2026 | | Initiated Coverage | $4.00 | Outperform | 00.00% | View details for Leerink Partners rating of Nautilus Biotechnology (NASDAQ:NAUT) on 9/9/2026 |
PCRX Pacira BioSciences | $25.16 -2.8% | 9/9/2026 | | Initiated Coverage | $28.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Pacira BioSciences (NASDAQ:PCRX) on 9/9/2026 |
PHAT Phathom Pharmaceuticals | $8.37 -3.5% | 9/9/2026 | | Upgrade | | Hold | 00.00% | View details for Leerink Partners rating of Phathom Pharmaceuticals (NASDAQ:PHAT) on 9/9/2026 |
TEVA Teva Pharmaceutical Industries | $36.34 -1.4% | 9/9/2026 | | Initiated Coverage | $45.00 | Outperform | 00.00% | View details for Leerink Partners rating of Teva Pharmaceutical Industries (NYSE:TEVA) on 9/9/2026 |
VTRS Viatris | $16.38 -0.7% | 9/9/2026 | | Initiated Coverage | $20.00 | Outperform | 00.00% | View details for Leerink Partners rating of Viatris (NASDAQ:VTRS) on 9/9/2026 |
SPRY ARS Pharmaceuticals | $5.06 -3.3% | 9/8/2026 | | Set Price Target | $15.00 | | 00.00% | View details for Leerink Partners rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 9/8/2026 |
BLSM BlossomHill Therapeutics | $21.51 -2.2% | 9/1/2026 | | Initiated Coverage | $36.00 | Outperform | 00.00% | View details for Leerink Partners rating of BlossomHill Therapeutics (NASDAQ:BLSM) on 9/1/2026 |
LTGO Latigo Biotherapeutics | $21.54 -5.5% | 9/1/2026 | | Initiated Coverage | $36.00 | Outperform | 00.00% | View details for Leerink Partners rating of Latigo Biotherapeutics (NASDAQ:LTGO) on 9/1/2026 |
BLSM BlossomHill Therapeutics | $21.51 -2.2% | 9/1/2026 | | Initiated Coverage | $36.00 | Outperform | 00.00% | View details for Leerink Partners rating of BlossomHill Therapeutics (NASDAQ:BLSM) on 9/1/2026 |
LTGO Latigo Biotherapeutics | $21.54 -5.5% | 9/1/2026 | | Initiated Coverage | $36.00 | Outperform | 00.00% | View details for Leerink Partners rating of Latigo Biotherapeutics (NASDAQ:LTGO) on 9/1/2026 |
ATTO Attovia Therapeutics | $22.53 -1.4% | 8/31/2026 | | Initiated Coverage | $52.00 | Outperform | 00.00% | View details for Leerink Partners rating of Attovia Therapeutics (NASDAQ:ATTO) on 8/31/2026 |
SCTX Scribe Therapeutics | $29.47 +0.2% | 8/18/2026 | | Initiated Coverage | $37.00 | Outperform | 00.00% | View details for Leerink Partners rating of Scribe Therapeutics (NASDAQ:SCTX) on 8/18/2026 |
REGN Regeneron Pharmaceuticals | $793.26 -1.8% | 8/17/2026 | | Boost Price Target | $641.00 ➝ $824.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 8/17/2026 |
FRNM Freenome | $14.79 -6.1% | 8/14/2026 | | Initiated Coverage | $18.00 | Outperform | 00.00% | View details for Leerink Partners rating of Freenome (NASDAQ:FRNM) on 8/14/2026 |
LGND Ligand Pharmaceuticals | $289.25 +0.4% | 8/14/2026 | | Initiated Coverage | $330.00 | Outperform | 00.00% | View details for Leerink Partners rating of Ligand Pharmaceuticals (NASDAQ:LGND) on 8/14/2026 |
SMMT Summit Therapeutics | $17.00 -3.1% | 8/12/2026 | | Upgrade | $12.00 ➝ $13.00 | Underperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Summit Therapeutics (NASDAQ:SMMT) on 8/12/2026 |
CAH Cardinal Health | $235.96 -1.7% | 8/11/2026 | | Set Price Target | $292.00 | | 00.00% | View details for Leerink Partners rating of Cardinal Health (NYSE:CAH) on 8/11/2026 |
TENX Tenax Therapeutics | $1.95 -8.5% | 8/11/2026 | | Set Price Target | $4.00 | | 00.00% | View details for Leerink Partners rating of Tenax Therapeutics (NASDAQ:TENX) on 8/11/2026 |
IPHA Innate Pharma | $1.88 -3.6% | 8/11/2026 | | Upgrade | $4.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Innate Pharma (NASDAQ:IPHA) on 8/11/2026 |
NTRA Natera | $326.14 -1.3% | 8/7/2026 | | Set Price Target | $330.00 | | 00.00% | View details for Leerink Partners rating of Natera (NASDAQ:NTRA) on 8/7/2026 |
AKBA Akebia Therapeutics | $0.95 -0.8% | 8/7/2026 | | Downgrade | $1.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Akebia Therapeutics (NASDAQ:AKBA) on 8/7/2026 |
HALO Halozyme Therapeutics | $107.00 -0.4% | 8/7/2026 | | Upgrade | $83.00 ➝ $110.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Halozyme Therapeutics (NASDAQ:HALO) on 8/7/2026 |
GDRX GoodRx | $3.35 +0.3% | 8/6/2026 | | Set Price Target | $5.00 | | 00.00% | View details for Leerink Partners rating of GoodRx (NASDAQ:GDRX) on 8/6/2026 |
EXEL Exelixis | $57.43 -1.5% | 8/6/2026 | | Downgrade | $52.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Exelixis (NASDAQ:EXEL) on 8/6/2026 |
PODD Insulet | $134.68 -2.3% | 8/6/2026 | | Downgrade | $247.00 ➝ $145.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Insulet (NASDAQ:PODD) on 8/6/2026 |
This looks like plywood. It's not. (Ad) AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more electricity than an entire office building.
One new chip, which looks more like a piece of plywood than a processor, delivers similar performance on a fraction of the power. Tech investing veteran George Gilder says that efficiency gap could decide who wins the next stage of AI.
Gilder has identified three companies positioned around this power breakthrough, calling them the Trillion Dollar Triangle. See the three companies behind this AI power breakthrough now |
REPL Replimune Group | $13.24 -8.4% | 8/4/2026 | | Upgrade | $11.00 ➝ $17.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Replimune Group (NASDAQ:REPL) on 8/4/2026 |
KROS Keros Therapeutics | $11.17 -1.2% | 8/4/2026 | | Lower Price Target | $30.00 ➝ $23.00 | Outperform | 00.00% | View details for Leerink Partners rating of Keros Therapeutics (NASDAQ:KROS) on 8/4/2026 |
LNTH Lantheus | $100.39 -0.3% | 8/3/2026 | | Set Price Target | $102.50 | | 00.00% | View details for Leerink Partners rating of Lantheus (NASDAQ:LNTH) on 8/3/2026 |
INCY Incyte | $123.28 -2.2% | 8/3/2026 | | Boost Price Target | $131.00 ➝ $155.00 | Outperform | 00.00% | View details for Leerink Partners rating of Incyte (NASDAQ:INCY) on 8/3/2026 |
LNTH Lantheus | $100.39 -0.3% | 8/3/2026 | | Downgrade | | Strong-Buy ➝ Hold | 00.00% | View details for Leerink Partners rating of Lantheus (NASDAQ:LNTH) on 8/3/2026 |
BSX Boston Scientific | $43.03 -4.3% | 7/30/2026 | | Set Price Target | $60.00 | | 00.00% | View details for Leerink Partners rating of Boston Scientific (NYSE:BSX) on 7/30/2026 |
HUM Humana | $400.51 +0.1% | 7/30/2026 | | Upgrade | $513.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Humana (NYSE:HUM) on 7/30/2026 |
GOSS Gossamer Bio | $0.14 -10.8% | 7/28/2026 | | Upgrade | $1.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Gossamer Bio (NASDAQ:GOSS) on 7/28/2026 |
EW Edwards Lifesciences | $86.70 +0.6% | 7/24/2026 | | Upgrade | $87.00 ➝ $101.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Edwards Lifesciences (NYSE:EW) on 7/24/2026 |
MEDP Medpace | $583.16 -0.5% | 7/23/2026 | | Set Price Target | $620.00 | | 00.00% | View details for Leerink Partners rating of Medpace (NASDAQ:MEDP) on 7/23/2026 |
PGNY Progyny | $27.08 -0.1% | 7/22/2026 | | Set Price Target | $38.00 | | 00.00% | View details for Leerink Partners rating of Progyny (NASDAQ:PGNY) on 7/22/2026 |
GILD Gilead Sciences | $144.81 -0.6% | 7/21/2026 | | Downgrade | $146.00 ➝ $127.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Gilead Sciences (NASDAQ:GILD) on 7/21/2026 |
STTK Shattuck Labs | $6.15 -2.8% | 7/20/2026 | | Initiated Coverage | $16.00 | Outperform | 00.00% | View details for Leerink Partners rating of Shattuck Labs (NASDAQ:STTK) on 7/20/2026 |
ELV Elevance Health | $416.58 +5.0% | 7/17/2026 | | Boost Price Target | $364.00 ➝ $395.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Elevance Health (NYSE:ELV) on 7/17/2026 |
ILMN Illumina | $201.27 -1.8% | 7/17/2026 | | Boost Price Target | $175.00 ➝ $210.00 | Outperform | 00.00% | View details for Leerink Partners rating of Illumina (NASDAQ:ILMN) on 7/17/2026 |
TXG 10x Genomics | $66.38 -1.4% | 7/17/2026 | | Boost Price Target | $23.00 ➝ $40.00 | Market Perform | 00.00% | View details for Leerink Partners rating of 10x Genomics (NASDAQ:TXG) on 7/17/2026 |
ISRG Intuitive Surgical | $360.46 +2.0% | 7/17/2026 | | Lower Price Target | $573.00 ➝ $454.00 | Outperform | 00.00% | View details for Leerink Partners rating of Intuitive Surgical (NASDAQ:ISRG) on 7/17/2026 |
TWST Twist Bioscience | $126.85 +1.1% | 7/16/2026 | | Set Price Target | $110.00 | | 00.00% | View details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 7/16/2026 |
KARD Kardigan | $18.69 -5.0% | 7/13/2026 | | Initiated Coverage | $37.00 | Outperform | 00.00% | View details for Leerink Partners rating of Kardigan (NASDAQ:KARD) on 7/13/2026 |
NGEN NervGen Pharma | $2.16 +1.4% | 7/13/2026 | | Initiated Coverage | $10.00 | Outperform | 00.00% | View details for Leerink Partners rating of NervGen Pharma (NASDAQ:NGEN) on 7/13/2026 |
WHWK Whitehawk Therapeutics | $4.07 -2.9% | 7/13/2026 | | Initiated Coverage | $9.00 | Outperform | 00.00% | View details for Leerink Partners rating of Whitehawk Therapeutics (NASDAQ:WHWK) on 7/13/2026 |
BRKR Bruker | $53.56 -1.6% | 7/7/2026 | | Boost Price Target | $60.00 ➝ $70.00 | Outperform | 00.00% | View details for Leerink Partners rating of Bruker (NASDAQ:BRKR) on 7/7/2026 |
AVTX Avalo Therapeutics | $17.18 -5.7% | 7/6/2026 | | Initiated Coverage | $38.00 | Outperform | 00.00% | View details for Leerink Partners rating of Avalo Therapeutics (NASDAQ:AVTX) on 7/6/2026 |
PBLS Parabilis Medicines | $36.32 -6.3% | 7/6/2026 | | Initiated Coverage | $40.00 | Outperform | 00.00% | View details for Leerink Partners rating of Parabilis Medicines (NASDAQ:PBLS) on 7/6/2026 |
PYXS Pyxis Oncology | $3.27 -3.3% | 7/2/2026 | | Lower Price Target | $9.00 ➝ $7.00 | Outperform | 00.00% | View details for Leerink Partners rating of Pyxis Oncology (NASDAQ:PYXS) on 7/2/2026 |
MLTX MoonLake Immunotherapeutics | $13.18 -3.9% | 7/1/2026 | | Boost Price Target | $24.00 ➝ $29.00 | Outperform | 00.00% | View details for Leerink Partners rating of MoonLake Immunotherapeutics (NASDAQ:MLTX) on 7/1/2026 |
ABVX Abivax | $115.95 -2.9% | 6/30/2026 | | Boost Price Target | $140.00 ➝ $148.00 | Outperform | 00.00% | View details for Leerink Partners rating of Abivax (NASDAQ:ABVX) on 6/30/2026 |
TECH Bio-Techne | $72.08 -0.2% | 6/25/2026 | | Set Price Target | $73.00 | | 00.00% | View details for Leerink Partners rating of Bio-Techne (NASDAQ:TECH) on 6/25/2026 |
LLY Eli Lilly and Company | $1,122.74 -0.1% | 6/25/2026 | | Boost Price Target | $1,119.00 ➝ $1,232.00 | Outperform | 00.00% | View details for Leerink Partners rating of Eli Lilly and Company (NYSE:LLY) on 6/25/2026 |
IONS Ionis Pharmaceuticals | $55.65 -0.7% | 6/25/2026 | | Boost Price Target | $122.00 ➝ $129.00 | Outperform | 00.00% | View details for Leerink Partners rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 6/25/2026 |
SPRY ARS Pharmaceuticals | $5.06 -3.3% | 6/25/2026 | | Lower Price Target | $25.00 ➝ $24.00 | Outperform | 00.00% | View details for Leerink Partners rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 6/25/2026 |
TECH Bio-Techne | $72.08 -0.2% | 6/25/2026 | | Downgrade | | Strong-Buy ➝ Hold | 00.00% | View details for Leerink Partners rating of Bio-Techne (NASDAQ:TECH) on 6/25/2026 |
QNCX Quince Therapeutics | $28.96 -4.5% | 6/24/2026 | | Initiated Coverage | $80.00 | Outperform | 00.00% | View details for Leerink Partners rating of Quince Therapeutics (NASDAQ:QNCX) on 6/24/2026 |
RAPP Rapport Therapeutics | $43.46 -1.0% | 6/24/2026 | | Initiated Coverage | $52.00 | Outperform | 00.00% | View details for Leerink Partners rating of Rapport Therapeutics (NASDAQ:RAPP) on 6/24/2026 |
RGNX REGENXBIO | $8.56 -1.9% | 6/22/2026 | | Boost Price Target | $17.00 ➝ $18.00 | Outperform | 00.00% | View details for Leerink Partners rating of REGENXBIO (NASDAQ:RGNX) on 6/22/2026 |
DFTX Definium Therapeutics | $37.73 -0.7% | 6/22/2026 | | Set Price Target | $30.00 ➝ $52.00 | Outperform | 00.00% | View details for Leerink Partners rating of Definium Therapeutics (NASDAQ:DFTX) on 6/22/2026 |
ALT Altimmune | $3.29 -1.8% | 6/22/2026 | | Initiated Coverage | $10.00 | Outperform | 00.00% | View details for Leerink Partners rating of Altimmune (NASDAQ:ALT) on 6/22/2026 |
QURE uniQure | $44.47 -3.3% | 6/18/2026 | | Boost Price Target | $36.00 ➝ $70.00 | Outperform | 00.00% | View details for Leerink Partners rating of uniQure (NASDAQ:QURE) on 6/18/2026 |
ARWR Arrowhead Pharmaceuticals | $82.76 +0.2% | 6/17/2026 | | Boost Price Target | $61.00 ➝ $72.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 6/17/2026 |
IONS Ionis Pharmaceuticals | $55.65 -0.7% | 6/17/2026 | | Boost Price Target | $114.00 ➝ $122.00 | Outperform | 00.00% | View details for Leerink Partners rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 6/17/2026 |
UNH UnitedHealth Group | $387.69 -1.4% | 6/17/2026 | | Boost Price Target | $400.00 ➝ $462.00 | Outperform | 00.00% | View details for Leerink Partners rating of UnitedHealth Group (NYSE:UNH) on 6/17/2026 |
EWTX Edgewise Therapeutics | $42.90 -1.1% | 6/16/2026 | | Set Price Target | $52.00 | | 00.00% | View details for Leerink Partners rating of Edgewise Therapeutics (NASDAQ:EWTX) on 6/16/2026 |
SABS SAB Biotherapeutics | $3.42 -1.7% | 6/15/2026 | | Boost Price Target | $7.00 ➝ $12.00 | Outperform | 00.00% | View details for Leerink Partners rating of SAB Biotherapeutics (NASDAQ:SABS) on 6/15/2026 |
PRCT PROCEPT BioRobotics | $20.07 -3.2% | 6/11/2026 | | Downgrade | $31.00 ➝ $29.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of PROCEPT BioRobotics (NASDAQ:PRCT) on 6/11/2026 |
TNGX Tango Therapeutics | $23.37 -2.6% | 6/8/2026 | | Boost Price Target | $55.00 ➝ $69.00 | Outperform | 00.00% | View details for Leerink Partners rating of Tango Therapeutics (NASDAQ:TNGX) on 6/8/2026 |
SYK Stryker | $269.98 -2.0% | 6/5/2026 | | Lower Price Target | $410.00 ➝ $407.00 | Outperform | 00.00% | View details for Leerink Partners rating of Stryker (NYSE:SYK) on 6/5/2026 |
NBTX Nanobiotix | $37.60 +2.6% | 6/4/2026 | | Boost Price Target | $37.00 ➝ $46.00 | Outperform | 00.00% | View details for Leerink Partners rating of Nanobiotix (NASDAQ:NBTX) on 6/4/2026 |
ABSI Absci | $8.24 -4.7% | 6/4/2026 | | Initiated Coverage | $12.00 | Outperform | 00.00% | View details for Leerink Partners rating of Absci (NASDAQ:ABSI) on 6/4/2026 |
MDT Medtronic | $91.60 -0.3% | 6/4/2026 | | Lower Price Target | $117.00 ➝ $104.00 | Outperform | 00.00% | View details for Leerink Partners rating of Medtronic (NYSE:MDT) on 6/4/2026 |
VIR Vir Biotechnology | $10.58 -2.1% | 6/3/2026 | | Boost Price Target | $20.00 ➝ $21.00 | Outperform | 00.00% | View details for Leerink Partners rating of Vir Biotechnology (NASDAQ:VIR) on 6/3/2026 |
Bezos… DOOMED (Ad) A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry.
James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing September 25. Watch James Altucher's free video breakdown before the September 25 deadline. |
CELC Celcuity | $85.49 -5.1% | 6/2/2026 | | Set Price Target | $155.00 | | 00.00% | View details for Leerink Partners rating of Celcuity (NASDAQ:CELC) on 6/2/2026 |
FULC Fulcrum Therapeutics | $3.80 -1.0% | 6/2/2026 | | Downgrade | $4.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Fulcrum Therapeutics (NASDAQ:FULC) on 6/2/2026 |
XFOR X4 Pharmaceuticals | $3.40 -5.6% | 6/2/2026 | | Initiated Coverage | $12.00 | Outperform | 00.00% | View details for Leerink Partners rating of X4 Pharmaceuticals (NASDAQ:XFOR) on 6/2/2026 |
ICLR Icon | $165.69 +3.9% | 5/28/2026 | | Set Price Target | $145.00 | | 00.00% | View details for Leerink Partners rating of Icon (NASDAQ:ICLR) on 5/28/2026 |
BSX Boston Scientific | $43.03 -4.3% | 5/28/2026 | | Lower Price Target | $87.00 ➝ $74.00 | Outperform | 00.00% | View details for Leerink Partners rating of Boston Scientific (NYSE:BSX) on 5/28/2026 |
EQ Equillium | $2.42 -5.5% | 5/28/2026 | | Upgrade | $1.00 ➝ $6.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Equillium (NASDAQ:EQ) on 5/28/2026 |
LLY Eli Lilly and Company | $1,122.74 -0.1% | 5/26/2026 | | Set Price Target | $1,119.00 | | 00.00% | View details for Leerink Partners rating of Eli Lilly and Company (NYSE:LLY) on 5/26/2026 |
SPTX Seaport Therapeutics | $23.28 +7.0% | 5/26/2026 | | Initiated Coverage | $35.00 | Outperform | 00.00% | View details for Leerink Partners rating of Seaport Therapeutics (NASDAQ:SPTX) on 5/26/2026 |
TWST Twist Bioscience | $126.85 +1.1% | 5/22/2026 | | Set Price Target | $80.00 | | 00.00% | View details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 5/22/2026 |
EHC Encompass Health | $120.95 -0.5% | 5/22/2026 | | Set Price Target | $152.00 | | 00.00% | View details for Leerink Partners rating of Encompass Health (NYSE:EHC) on 5/22/2026 |